Regado Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
23
Active:18
Completed:4
Trial Phases
3 Phases
Phase 1:6
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (60.0%)Phase 2
2 (20.0%)Phase 3
2 (20.0%)Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Subcutaneous RB006 3.0 mg/kgDrug: Subcutaneous RB006 0.5 mg/kgDrug: Subcutaneous RB006 1.0 mg/kgDrug: Subcutaneous RB006 2.0 mgDrug: Placebo
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01872572
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
Phase 3
Terminated
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: pegnivacogin/anivamersen
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 3232
- Registration Number
- NCT01848106
- Locations
- 🇺🇸
Black Hills Cardiovascular Research, Rapid City, South Dakota, United States
A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 640
- Registration Number
- NCT00932100
- Locations
- 🇺🇸
Heart Center Research LLC, Huntsville, Alabama, United States
🇺🇸Mercy Heart & Vascular Institute, Sacramento, California, United States
🇺🇸Sutter Medical Center - Sacramento, Sacramento, California, United States
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00715455
- Locations
- 🇺🇸
The Care Group, LLC, Indianapolis, Indiana, United States
🇺🇸Henry Ford, Detroit, Michigan, United States
🇺🇸UNC, Chapel Hill, North Carolina, United States
News
No news found